Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib and Apatinib as Neoadjuvant Therapy for HRD-Positive Advanced Ovarian Cancer
NCT07033819Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: R0 Resection Rate at 4 months. Started Jun 2025; status: recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07033819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033819.